Lonsurf (trifluridine/tipiracil) / Otsuka 
Welcome,         Profile    Billing    Logout  
 6 Diseases   125 Trials   125 Trials   2571 News 


«12...22232425262728293031323334»
  • ||||||||||  Real-world data on treatment patterns of advanced CRC in third-line and beyond. (Level 1, West Hall - Poster Board C6) -  Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_811;    
    Recycling of chemotherapy and biologics in the late line setting is common and occurs more frequently than switching to a drug regimen with an alternative mechanism of action. Research Funding: NantHealth
  • ||||||||||  irinotecan / Generic mfg.
    Real-world treatment attrition rates in advanced esophagogastric cancer. (Level 1, West Hall - Poster Board B14) -  Dec 10, 2019 - Abstract #ASCOGI2020ASCO-GI_257;    
    The steep attrition rates between therapies highlight the unmet need for more efficacious earlier-line treatment options for patients with advanced EGC. Research Funding: None
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102, Stivarga (regorafenib) / Bayer
    Clinical, Review, Journal:  Beyond Second-Line Therapy in Patients With Metastatic Colorectal Cancer: A Systematic Review. (Pubmed Central) -  Nov 28, 2019   
    Patient choice and quality of life at this stage of treatment should also be considered when choosing an appropriate therapy. These findings support the introduction of an approved agent such as trifluridine/tipiracil or regorafenib beyond the second-line before any rechallenge in patients with mCRC who have failed second-line treatment.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  TAS102 in Combination With NAL-IRI in Advanced GI Cancers (clinicaltrials.gov) -  Nov 27, 2019   
    P1/2,  N=64, Recruiting, 
    These findings support the introduction of an approved agent such as trifluridine/tipiracil or regorafenib beyond the second-line before any rechallenge in patients with mCRC who have failed second-line treatment. Trial completion date: Feb 2020 --> Feb 2021 | Trial primary completion date: Feb 2020 --> Feb 2021
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, TAS / 102
    SURVEY ON TREATMENT WITH TAS 102 IN PATIENTS WITH METASTATIC COLORECTAL CANCER () -  Nov 23, 2019 - Abstract #AIOM2019AIOM_30;    
    Thanks to this survey we have tested the Sicilian oncological network and it has been proved that TAS 102 is adequately and correctly used, although it was introduced later than in other Italian regions. No unexpected toxicity emerged from this real life experience on the use of this drug and it also seems to be well tolerated by elderly pts (over 75) who represent about half of the examined population.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Renal Impairment (clinicaltrials.gov) -  Nov 20, 2019   
    P1,  N=48, Active, not recruiting, 
    No unexpected toxicity emerged from this real life experience on the use of this drug and it also seems to be well tolerated by elderly pts (over 75) who represent about half of the examined population. Recruiting --> Active, not recruiting | Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka
    Trial completion date, Trial primary completion date:  Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases (clinicaltrials.gov) -  Nov 19, 2019   
    P1,  N=24, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Jul 2019 --> Dec 2019 | Trial primary completion date: Jul 2019 --> Dec 2019 Trial completion date: Sep 2020 --> Dec 2021 | Trial primary completion date: Sep 2019 --> Dec 2020
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, Journal:  Temporary loss of consciousness during cetuximab treatment of a patient with metastatic colon cancer: a case report. (Pubmed Central) -  Oct 23, 2019   
    Prospective clinical trials should be performed to explore the optimal duration of maintenance nivolumab. This case report reminds clinicians that LOC can be induced without severe hypomagnesemia or QTc prolongation, during anti-EGFR antibody treatment for metastatic colorectal cancer even while under carefully monitored magnesium supplementation.
  • ||||||||||  Herceptin (trastuzumab) / Roche, paclitaxel / Generic Mfg., Opdivo (nivolumab) / Ono Pharma, BMS
    Review, Journal:  Targeted and novel therapy in advanced gastric cancer. (Pubmed Central) -  Oct 22, 2019   
    Pembrolizumab has demonstrated more than 50% response rate in microsatellite instability-high tumors, 15% response rate in tumors expressing programmed death ligand 1, and non-inferior outcome in first-line treatment compared to chemotherapy. This review summarizes the current state and progress of research on targeted therapy for advanced GC.